Amgen Research (Munich) Gmbh

Amgen Inc.

Laboratoire Francais Du Fractionnement Et Des Biotechnologies

Scil Technology Gmbh

Amgen Research Gmbh

Cornelius Pompe

Peter Kufer

Tobias Raum

Patrick Hoffmann

Andreas Wolf

Benno Rattel

Johannes Brozy

Markus Münz

Matthias Friedrich

Pamela Bogner

Annie Bardat

Wolfgang Friess

Klaus Hellerbrand

Michael Siedler

Andreas Schuetz

Samuel Herberg

Sekhar Kanapuram

Ramil F Latypov

Balakumar Thangaraj

The present invention provides bispecific antibody constructs of a specific Fc modality characterized by comprising a first domain binding to PSMA, a second domain binding to an extracellular epitope of the human and theCD3ε chain and a third domain, which is the specific Fc modality. Moreover, the invention provides a polynucleotide, encoding the antibody construct, a vector comprising this polynucleotide, host cells, expressing the construct and a pharmaceutical composition comprising the same.

PSMA and CD3 bispecific T cell engaging antibody constructs

The present invention provides bispecific antibody constructs of a specific Fc modality characterized by comprising a first domain binding to a target cell surface antigen, a second domain binding to an extracellular epitope of the human and/or theCD3&#x3b5; chain and a third domain, which is the specific Fc modality. Moreover, the invention provides a polynucleotide, encoding the antibody construct, a vector comprising this polynucleotide, host cells, expressing the construct and a pharmaceutical composition comprising the same.

Bispecific T cell engaging antibody constructs

The present invention provides novel and stable pharmaceutical compositions comprising bispecific single chain antibody constructs, cyclodextrins and a buffer.

Pharmaceutical composition comprising bispecific antibody constructs

The present invention provides bispecific antibody constructs of a specific Fc modality characterized by comprising a first domain binding to BCMA, a second domain binding to an extracellular epitope of the human and/or theCD3&#x3b5; chain and a third domain, which is the specific Fc modality. Moreover, the invention provides a polynucleotide, encoding the antibody construct, a vector comprising this polynucleotide, host cells, expressing the construct and a pharmaceutical composition comprising the same.

BCMA and CD3 bispecific T cell engaging antibody constructs

The present invention provides bispecific antibody constructs of a specific Fc modality characterized by comprising a first domain binding to PSMA, a second domain binding to an extracellular epitope of the human and theCD3&#x3b5; chain and a third domain, which is the specific Fc modality. Moreover, the invention provides a polynucleotide, encoding the antibody construct, a vector comprising this polynucleotide, host cells, expressing the construct and a pharmaceutical composition comprising the same.

A stable pharmaceutical composition in liquid form or in solid form, containing factor VII. The composition is free of mannitol, sucrose, and any antioxidant.

Factor VII composition

The invention relates to a stable pharmaceutical composition in liquid form or in solid form, comprising factor VII, said composition being free of mannitol and of sucrose, or even also of any antioxidant.

The invention provides a polymer based material comprising a water binding agent present in an amount sufficient to chemically and/or physically absorb and/or adsorb water to prevent degradation of the polymer. The invention also provides a polymer based material comprising a plasticizer or organic solvent as well as a multi-component material or composite including materials encompassing a second polymer and/or an active agent. The invention further provides a pharmaceutical composition comprising the aforesaid polymer based material, which can be used for treatment of bone, cartilage and/or periodontal defects.

Biomaterial containing degradation stabilized polymer

The present invention relates to a polymer based material comprising a water binding agent, whereas the water binding agent is present in an amount sufficient to chemically and/or physically absorb and/or adsorb water to prevent degradation of the polymer. It also relates to a polymer based material which comprises a plasticizer or organic solvent as well as a multi-component material or composite including materials encompassing a second polymer and/or an active agent. Furthermore it relates to a method for manufacturing the polymer comprising material and use of the material for the preparation of a pharmaceutical composition to be used for treatment of bone, cartilage and/or periodontal defects. The invention also encompasses a kit using the polymeric material. Further, the present invention encompasses the use of a water binding agent for inhibiting water induced degradation of a polymer comprising material, for inducing blood clot stabilization in a polymer comprising material and for increasing storage stability in a polymer comprising material, wherein the water binding agent is not removed prior to application of the material.

Growing community of inventors

Munich, Germany

Cornelius Pompe